nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—abdominal aortic aneurysm	0.791	0.873	CbGaD
Thalidomide—PTGS2—abdominal aortic aneurysm	0.115	0.127	CbGaD
Thalidomide—Lenalidomide—PTGS2—abdominal aortic aneurysm	0.00202	0.518	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—abdominal aortic aneurysm	0.00188	0.482	CrCbGaD
Thalidomide—PTGS2—leg—abdominal aortic aneurysm	0.00161	0.0807	CbGeAlD
Thalidomide—NFKB1—connective tissue—abdominal aortic aneurysm	0.00154	0.0773	CbGeAlD
Thalidomide—PTGS2—hindlimb—abdominal aortic aneurysm	0.00144	0.0721	CbGeAlD
Thalidomide—NFKB1—kidney—abdominal aortic aneurysm	0.00132	0.0658	CbGeAlD
Thalidomide—FGFR2—connective tissue—abdominal aortic aneurysm	0.00116	0.0581	CbGeAlD
Thalidomide—FGFR2—kidney—abdominal aortic aneurysm	0.000988	0.0495	CbGeAlD
Thalidomide—CYP2C19—blood plasma—abdominal aortic aneurysm	0.000979	0.049	CbGeAlD
Thalidomide—PTGS1—artery—abdominal aortic aneurysm	0.000924	0.0462	CbGeAlD
Thalidomide—PTGS2—artery—abdominal aortic aneurysm	0.000883	0.0442	CbGeAlD
Thalidomide—CRBN—spinal cord—abdominal aortic aneurysm	0.000858	0.043	CbGeAlD
Thalidomide—CYP1A2—blood plasma—abdominal aortic aneurysm	0.000799	0.04	CbGeAlD
Thalidomide—CYP3A5—blood plasma—abdominal aortic aneurysm	0.000771	0.0386	CbGeAlD
Thalidomide—FGFR2—spinal cord—abdominal aortic aneurysm	0.000769	0.0385	CbGeAlD
Thalidomide—CYP2C9—blood plasma—abdominal aortic aneurysm	0.000759	0.038	CbGeAlD
Thalidomide—CYP2E1—blood plasma—abdominal aortic aneurysm	0.000719	0.036	CbGeAlD
Thalidomide—PTGS1—blood plasma—abdominal aortic aneurysm	0.000693	0.0347	CbGeAlD
Thalidomide—PTGS2—blood plasma—abdominal aortic aneurysm	0.000662	0.0332	CbGeAlD
Thalidomide—PTGS1—connective tissue—abdominal aortic aneurysm	0.000369	0.0185	CbGeAlD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—SERPINE1—abdominal aortic aneurysm	0.00036	0.00518	CbGpPWpGaD
Thalidomide—NFKB1—Rac1/Pak1/p38/MMP-2 pathway—NOS2—abdominal aortic aneurysm	0.00036	0.00517	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—CCL2—abdominal aortic aneurysm	0.00036	0.00516	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—PTGS2—abdominal aortic aneurysm	0.000358	0.00514	CbGpPWpGaD
Thalidomide—CYP1A1—kidney—abdominal aortic aneurysm	0.000357	0.0179	CbGeAlD
Thalidomide—PTGS1—Eicosanoid Synthesis—PTGS2—abdominal aortic aneurysm	0.000357	0.00513	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—LDLR—abdominal aortic aneurysm	0.000356	0.00512	CbGpPWpGaD
Thalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—APOE—abdominal aortic aneurysm	0.000355	0.0051	CbGpPWpGaD
Thalidomide—PTGS2—connective tissue—abdominal aortic aneurysm	0.000353	0.0177	CbGeAlD
Thalidomide—CYP3A5—kidney—abdominal aortic aneurysm	0.000349	0.0175	CbGeAlD
Thalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—abdominal aortic aneurysm	0.000341	0.00489	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—MMP9—abdominal aortic aneurysm	0.000338	0.00485	CbGpPWpGaD
Thalidomide—TNF—Matrix Metalloproteinases—MMP9—abdominal aortic aneurysm	0.000337	0.00483	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—CCL2—abdominal aortic aneurysm	0.000333	0.00478	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—AGT—abdominal aortic aneurysm	0.000329	0.00473	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—CCL2—abdominal aortic aneurysm	0.000329	0.00472	CbGpPWpGaD
Thalidomide—CYP2E1—kidney—abdominal aortic aneurysm	0.000326	0.0163	CbGeAlD
Thalidomide—NFKB1—LPA receptor mediated events—MMP2—abdominal aortic aneurysm	0.000321	0.0046	CbGpPWpGaD
Thalidomide—TNF—amb2 Integrin signaling—MMP9—abdominal aortic aneurysm	0.00032	0.00459	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—SOD2—abdominal aortic aneurysm	0.00032	0.00459	CbGpPWpGaD
Thalidomide—FGFR2—Hair Follicle Development: Induction (Part 1 of 3)—NFKB1—abdominal aortic aneurysm	0.000317	0.00455	CbGpPWpGaD
Thalidomide—TNF—amb2 Integrin signaling—NFKB1—abdominal aortic aneurysm	0.000316	0.00454	CbGpPWpGaD
Thalidomide—CYP1A1—Melatonin metabolism and effects—APOE—abdominal aortic aneurysm	0.000316	0.00454	CbGpPWpGaD
Thalidomide—PTGS1—kidney—abdominal aortic aneurysm	0.000314	0.0157	CbGeAlD
Thalidomide—NFKB1—AGE/RAGE pathway—MMP2—abdominal aortic aneurysm	0.000313	0.00449	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—AGT—abdominal aortic aneurysm	0.000312	0.00449	CbGpPWpGaD
Thalidomide—NFKB1—Oncostatin M Signaling Pathway—SERPINE1—abdominal aortic aneurysm	0.000311	0.00446	CbGpPWpGaD
Thalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—NFKB1—abdominal aortic aneurysm	0.000309	0.00443	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—CCL2—abdominal aortic aneurysm	0.000308	0.00442	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—SERPINE1—abdominal aortic aneurysm	0.000307	0.00441	CbGpPWpGaD
Thalidomide—PTGS2—kidney—abdominal aortic aneurysm	0.0003	0.015	CbGeAlD
Thalidomide—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—abdominal aortic aneurysm	0.000299	0.00429	CbGpPWpGaD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—abdominal aortic aneurysm	0.000298	0.00427	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—SOD2—abdominal aortic aneurysm	0.000289	0.00415	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—SERPINE1—abdominal aortic aneurysm	0.000287	0.00413	CbGpPWpGaD
Thalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—abdominal aortic aneurysm	0.000285	0.0041	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—LDLR—abdominal aortic aneurysm	0.000283	0.00406	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—NFKB1—abdominal aortic aneurysm	0.000282	0.00404	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—SERPINE1—abdominal aortic aneurysm	0.000275	0.00394	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—PTGS2—abdominal aortic aneurysm	0.000273	0.00391	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—AAAS—abdominal aortic aneurysm	0.000272	0.00391	CbGpPWpGaD
Thalidomide—FGFR2—FGF signaling pathway—MMP9—abdominal aortic aneurysm	0.000262	0.00376	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—CCL2—abdominal aortic aneurysm	0.000261	0.00375	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—APOE—abdominal aortic aneurysm	0.000258	0.00371	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—APOE—abdominal aortic aneurysm	0.000258	0.00371	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—MMP9—abdominal aortic aneurysm	0.000257	0.00369	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—NFKB1—abdominal aortic aneurysm	0.000255	0.00367	CbGpPWpGaD
Thalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—abdominal aortic aneurysm	0.000255	0.00366	CbGpPWpGaD
Thalidomide—TNF—TWEAK Signaling Pathway—NFKB1—abdominal aortic aneurysm	0.000254	0.00365	CbGpPWpGaD
Thalidomide—CYP2E1—spinal cord—abdominal aortic aneurysm	0.000254	0.0127	CbGeAlD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—CCL2—abdominal aortic aneurysm	0.000252	0.00362	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AGT—abdominal aortic aneurysm	0.000251	0.0036	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—CCL2—abdominal aortic aneurysm	0.000251	0.0036	CbGpPWpGaD
Thalidomide—PTGS1—spinal cord—abdominal aortic aneurysm	0.000245	0.0122	CbGeAlD
Thalidomide—NFKB1—Selenium Micronutrient Network—SERPINE1—abdominal aortic aneurysm	0.000244	0.0035	CbGpPWpGaD
Thalidomide—NFKB1—LPA receptor mediated events—MMP9—abdominal aortic aneurysm	0.000241	0.00346	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor—NFKB1—abdominal aortic aneurysm	0.000237	0.0034	CbGpPWpGaD
Thalidomide—TNF—TNF receptor signaling pathway —NFKB1—abdominal aortic aneurysm	0.000237	0.0034	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—CDKN2A—abdominal aortic aneurysm	0.000236	0.00339	CbGpPWpGaD
Thalidomide—NFKB1—AGE/RAGE pathway—MMP9—abdominal aortic aneurysm	0.000235	0.00338	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—SERPINE1—abdominal aortic aneurysm	0.000234	0.00336	CbGpPWpGaD
Thalidomide—PTGS2—spinal cord—abdominal aortic aneurysm	0.000234	0.0117	CbGeAlD
Thalidomide—TNF—Ceramide signaling pathway—NFKB1—abdominal aortic aneurysm	0.000229	0.00328	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways in Glioblastoma—CDKN2A—abdominal aortic aneurysm	0.000229	0.00328	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—SOD2—abdominal aortic aneurysm	0.000225	0.00323	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—CDKN2A—abdominal aortic aneurysm	0.000222	0.00318	CbGpPWpGaD
Thalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—NFKB1—abdominal aortic aneurysm	0.000221	0.00318	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—NFKB1—abdominal aortic aneurysm	0.000218	0.00313	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—PTGS2—abdominal aortic aneurysm	0.000213	0.00306	CbGpPWpGaD
Thalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—NFKB1—abdominal aortic aneurysm	0.000211	0.00303	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—NFKB1—abdominal aortic aneurysm	0.000208	0.00299	CbGpPWpGaD
Thalidomide—TNF—Cardiac Hypertrophic Response—NFKB1—abdominal aortic aneurysm	0.000205	0.00295	CbGpPWpGaD
Thalidomide—CYP1A2—Melatonin metabolism and effects—APOE—abdominal aortic aneurysm	0.000201	0.00289	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—CCL2—abdominal aortic aneurysm	0.000199	0.00286	CbGpPWpGaD
Thalidomide—PTGS1—Arachidonic acid metabolism—PTGS2—abdominal aortic aneurysm	0.000199	0.00285	CbGpPWpGaD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—abdominal aortic aneurysm	0.000198	0.00284	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—CCL2—abdominal aortic aneurysm	0.000192	0.00276	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—CDKN2A—abdominal aortic aneurysm	0.000192	0.00276	CbGpPWpGaD
Thalidomide—CYP1A1—Melatonin metabolism and effects—NFKB1—abdominal aortic aneurysm	0.000188	0.0027	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—SERPINE1—abdominal aortic aneurysm	0.000186	0.00267	CbGpPWpGaD
Thalidomide—CYP1A1—Oxidative Stress—NFKB1—abdominal aortic aneurysm	0.000183	0.00263	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—abdominal aortic aneurysm	0.000182	0.00261	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—CDKN2A—abdominal aortic aneurysm	0.00018	0.00259	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—SOD2—abdominal aortic aneurysm	0.000179	0.00257	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—NFKB1—abdominal aortic aneurysm	0.000177	0.00255	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—AGT—abdominal aortic aneurysm	0.000177	0.00254	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—SELL—abdominal aortic aneurysm	0.000175	0.00252	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—NOS2—abdominal aortic aneurysm	0.000174	0.00251	CbGpPWpGaD
Thalidomide—FGFR2—Ectoderm Differentiation—CCL2—abdominal aortic aneurysm	0.000173	0.00248	CbGpPWpGaD
Thalidomide—TNF—Signaling events mediated by HDAC Class I—NFKB1—abdominal aortic aneurysm	0.000169	0.00243	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—SELL—abdominal aortic aneurysm	0.000167	0.00239	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—PTGS2—abdominal aortic aneurysm	0.000162	0.00233	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—SOD2—abdominal aortic aneurysm	0.000157	0.00226	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—CCL2—abdominal aortic aneurysm	0.000157	0.00226	CbGpPWpGaD
Thalidomide—FGFR2—Neural Crest Differentiation—NFKB1—abdominal aortic aneurysm	0.000157	0.00226	CbGpPWpGaD
Thalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—NFKB1—abdominal aortic aneurysm	0.000157	0.00225	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—CCL2—abdominal aortic aneurysm	0.000155	0.00223	CbGpPWpGaD
Thalidomide—CYP2C19—Melatonin metabolism and effects—NFKB1—abdominal aortic aneurysm	0.000154	0.00221	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—abdominal aortic aneurysm	0.00015	0.00215	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—abdominal aortic aneurysm	0.000146	0.0021	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—NFKB1—abdominal aortic aneurysm	0.000146	0.0021	CbGpPWpGaD
Thalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—abdominal aortic aneurysm	0.000146	0.0021	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—SERPINE1—abdominal aortic aneurysm	0.000145	0.00208	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—NFKB1—abdominal aortic aneurysm	0.000141	0.00202	CbGpPWpGaD
Thalidomide—CYP1A1—Arachidonic acid metabolism—PTGS2—abdominal aortic aneurysm	0.00014	0.00201	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—SERPINE1—abdominal aortic aneurysm	0.000136	0.00195	CbGpPWpGaD
Thalidomide—TNF—TNF alpha Signaling Pathway—NFKB1—abdominal aortic aneurysm	0.000136	0.00195	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—abdominal aortic aneurysm	0.00013	0.00186	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—PTGS2—abdominal aortic aneurysm	0.000128	0.00184	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—PTGS2—abdominal aortic aneurysm	0.000126	0.00182	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—CDKN2A—abdominal aortic aneurysm	0.000125	0.0018	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—NFKB1—abdominal aortic aneurysm	0.000125	0.0018	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—CCL2—abdominal aortic aneurysm	0.000123	0.00177	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—MMP9—abdominal aortic aneurysm	0.000122	0.00175	CbGpPWpGaD
Thalidomide—CYP1A2—Melatonin metabolism and effects—NFKB1—abdominal aortic aneurysm	0.00012	0.00172	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NCF1—abdominal aortic aneurysm	0.00012	0.00172	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—SERPINE1—abdominal aortic aneurysm	0.000115	0.00165	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—PTGS2—abdominal aortic aneurysm	0.000115	0.00165	CbGpPWpGaD
Thalidomide—CYP2C19—Arachidonic acid metabolism—PTGS2—abdominal aortic aneurysm	0.000115	0.00164	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NCF1—abdominal aortic aneurysm	0.000114	0.00163	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—MMP9—abdominal aortic aneurysm	0.000113	0.00162	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—abdominal aortic aneurysm	0.000111	0.0016	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—AGT—abdominal aortic aneurysm	0.000111	0.00159	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—NFKB1—abdominal aortic aneurysm	0.00011	0.00158	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—abdominal aortic aneurysm	0.000109	0.00156	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—NOS2—abdominal aortic aneurysm	0.000108	0.00155	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SELL—abdominal aortic aneurysm	0.000106	0.00153	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—abdominal aortic aneurysm	0.000105	0.00151	CbGpPWpGaD
Thalidomide—CYP2C9—Arachidonic acid metabolism—PTGS2—abdominal aortic aneurysm	0.000104	0.0015	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SELL—abdominal aortic aneurysm	0.000101	0.00145	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—NFKB1—abdominal aortic aneurysm	0.0001	0.00144	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—NFKB1—abdominal aortic aneurysm	9.77e-05	0.0014	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CCL2—abdominal aortic aneurysm	9.73e-05	0.0014	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—abdominal aortic aneurysm	9.54e-05	0.00137	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—CDKN2A—abdominal aortic aneurysm	9.46e-05	0.00136	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—NFKB1—abdominal aortic aneurysm	9.28e-05	0.00133	CbGpPWpGaD
Thalidomide—FGFR2—Disease—LRP1—abdominal aortic aneurysm	8.98e-05	0.00129	CbGpPWpGaD
Thalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—abdominal aortic aneurysm	8.93e-05	0.00128	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—NFKB1—abdominal aortic aneurysm	8.91e-05	0.00128	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AAAS—abdominal aortic aneurysm	8.89e-05	0.00128	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—abdominal aortic aneurysm	8.73e-05	0.00125	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—NFKB1—abdominal aortic aneurysm	8.71e-05	0.00125	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AAAS—abdominal aortic aneurysm	8.44e-05	0.00121	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—NFKB1—abdominal aortic aneurysm	8.39e-05	0.00121	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—abdominal aortic aneurysm	8.28e-05	0.00119	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	8e-05	0.00115	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AAAS—abdominal aortic aneurysm	7.79e-05	0.00112	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—NFKB1—abdominal aortic aneurysm	7.58e-05	0.00109	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—abdominal aortic aneurysm	7.48e-05	0.00107	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NCF1—abdominal aortic aneurysm	7.26e-05	0.00104	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MMP9—abdominal aortic aneurysm	6.96e-05	0.001	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NCF1—abdominal aortic aneurysm	6.89e-05	0.00099	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NFKB1—abdominal aortic aneurysm	6.83e-05	0.000981	CbGpPWpGaD
Thalidomide—FGFR2—Disease—LDLR—abdominal aortic aneurysm	6.8e-05	0.000977	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LRP1—abdominal aortic aneurysm	6.62e-05	0.000951	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NCF1—abdominal aortic aneurysm	6.36e-05	0.000914	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	6.35e-05	0.000912	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LRP1—abdominal aortic aneurysm	6.29e-05	0.000903	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP2—abdominal aortic aneurysm	6.25e-05	0.000898	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—P2RY12—abdominal aortic aneurysm	6.2e-05	0.00089	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—P2RY12—abdominal aortic aneurysm	5.88e-05	0.000844	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	5.64e-05	0.00081	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LDLR—abdominal aortic aneurysm	5.02e-05	0.000721	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LDLR—abdominal aortic aneurysm	4.76e-05	0.000684	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP2—abdominal aortic aneurysm	4.76e-05	0.000684	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—MMP9—abdominal aortic aneurysm	4.7e-05	0.000675	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NCF1—abdominal aortic aneurysm	4.7e-05	0.000674	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—abdominal aortic aneurysm	4.69e-05	0.000673	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	4.61e-05	0.000663	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LRP1—abdominal aortic aneurysm	4.46e-05	0.00064	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NCF1—abdominal aortic aneurysm	4.46e-05	0.00064	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	4.23e-05	0.000607	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	4.21e-05	0.000604	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	4.14e-05	0.000595	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AAAS—abdominal aortic aneurysm	4.08e-05	0.000586	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NFKB1—abdominal aortic aneurysm	3.9e-05	0.000559	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AAAS—abdominal aortic aneurysm	3.87e-05	0.000556	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGTR1—abdominal aortic aneurysm	3.77e-05	0.000541	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NFKB1—abdominal aortic aneurysm	3.74e-05	0.000537	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	3.59e-05	0.000516	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP9—abdominal aortic aneurysm	3.58e-05	0.000514	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGTR1—abdominal aortic aneurysm	3.58e-05	0.000514	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—LDLR—abdominal aortic aneurysm	3.56e-05	0.000512	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NFKB1—abdominal aortic aneurysm	3.54e-05	0.000509	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOE—abdominal aortic aneurysm	3.52e-05	0.000506	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LDLR—abdominal aortic aneurysm	3.38e-05	0.000485	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP3—abdominal aortic aneurysm	3.36e-05	0.000483	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	3.36e-05	0.000482	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	3.29e-05	0.000472	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS2—abdominal aortic aneurysm	3.28e-05	0.000471	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AAAS—abdominal aortic aneurysm	3.24e-05	0.000465	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP3—abdominal aortic aneurysm	3.19e-05	0.000458	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NCF1—abdominal aortic aneurysm	3.16e-05	0.000454	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AAAS—abdominal aortic aneurysm	3.05e-05	0.000438	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AAAS—abdominal aortic aneurysm	3.04e-05	0.000437	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	2.98e-05	0.000428	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	2.92e-05	0.000419	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AAAS—abdominal aortic aneurysm	2.88e-05	0.000413	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	2.84e-05	0.000408	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LDLR—abdominal aortic aneurysm	2.83e-05	0.000406	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SERPINE1—abdominal aortic aneurysm	2.76e-05	0.000397	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LDLR—abdominal aortic aneurysm	2.66e-05	0.000382	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LDLR—abdominal aortic aneurysm	2.66e-05	0.000382	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGT—abdominal aortic aneurysm	2.65e-05	0.000381	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—abdominal aortic aneurysm	2.6e-05	0.000373	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGT—abdominal aortic aneurysm	2.52e-05	0.000362	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LDLR—abdominal aortic aneurysm	2.51e-05	0.000361	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—abdominal aortic aneurysm	2.47e-05	0.000354	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	2.44e-05	0.00035	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—abdominal aortic aneurysm	2.41e-05	0.000347	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	2.39e-05	0.000343	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AAAS—abdominal aortic aneurysm	2.35e-05	0.000338	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NFKB1—abdominal aortic aneurysm	2.27e-05	0.000326	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	2.22e-05	0.000319	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—abdominal aortic aneurysm	2.19e-05	0.000314	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	2.18e-05	0.000313	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AAAS—abdominal aortic aneurysm	2.15e-05	0.000308	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—abdominal aortic aneurysm	2.07e-05	0.000298	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LDLR—abdominal aortic aneurysm	2.05e-05	0.000295	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	2.04e-05	0.000293	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	2e-05	0.000287	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	1.94e-05	0.000278	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	1.9e-05	0.000273	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AGT—abdominal aortic aneurysm	1.88e-05	0.00027	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LDLR—abdominal aortic aneurysm	1.87e-05	0.000269	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	1.86e-05	0.000267	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—abdominal aortic aneurysm	1.85e-05	0.000265	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AAAS—abdominal aortic aneurysm	1.83e-05	0.000263	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—abdominal aortic aneurysm	1.75e-05	0.000251	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	1.64e-05	0.000235	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—abdominal aortic aneurysm	1.63e-05	0.000234	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LDLR—abdominal aortic aneurysm	1.6e-05	0.00023	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—abdominal aortic aneurysm	1.56e-05	0.000224	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—abdominal aortic aneurysm	1.5e-05	0.000215	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	1.49e-05	0.000214	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—abdominal aortic aneurysm	1.48e-05	0.000213	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKB1—abdominal aortic aneurysm	1.47e-05	0.000211	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—abdominal aortic aneurysm	1.47e-05	0.00021	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—abdominal aortic aneurysm	1.41e-05	0.000202	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—abdominal aortic aneurysm	1.4e-05	0.000202	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—abdominal aortic aneurysm	1.38e-05	0.000198	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—abdominal aortic aneurysm	1.38e-05	0.000198	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—abdominal aortic aneurysm	1.37e-05	0.000197	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—abdominal aortic aneurysm	1.33e-05	0.000191	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—abdominal aortic aneurysm	1.3e-05	0.000187	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	1.28e-05	0.000183	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—abdominal aortic aneurysm	1.26e-05	0.000182	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—abdominal aortic aneurysm	1.09e-05	0.000156	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—abdominal aortic aneurysm	1.06e-05	0.000153	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—abdominal aortic aneurysm	9.9e-06	0.000142	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—abdominal aortic aneurysm	9.7e-06	0.000139	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—abdominal aortic aneurysm	9.45e-06	0.000136	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—abdominal aortic aneurysm	9.43e-06	0.000135	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—abdominal aortic aneurysm	8.91e-06	0.000128	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—abdominal aortic aneurysm	8.46e-06	0.000122	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—abdominal aortic aneurysm	8.29e-06	0.000119	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—abdominal aortic aneurysm	7.29e-06	0.000105	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—abdominal aortic aneurysm	6.65e-06	9.55e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—abdominal aortic aneurysm	5.68e-06	8.16e-05	CbGpPWpGaD
